JAZZ - Earnings call transcript Q4 2021 | Jazz Pharmaceuticals plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Fourth Quarter 2021 Jazz Pharmaceuticals Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions].

As a reminder, this call may be recorded. to Investor call Relations. like Flynn, to now of Head would turn over the Andrea I

You begin. may

Andrea Flynn

Thank you, financial earlier we and on may reported posted presentation its also good also this today, the afternoon, everyone. quarter accompanying our the our to full which Today, Investors and refer section is year website. is to issued XXXX webcast results. of slide fourth The website. available Jazz Investors Pharmaceuticals release press

remind commercialization Executive forward-looking identify that made Bruce to to those Swisher, includes statements, cause We may statements statements. guidance our Executive are Head which factors to events, and Galá, potential Cozadd, no Iannone, webcast. today the including Officer; statements. events, in to milestones and uncertainties call North certain you development Chief materially Chief the that risks Dan involve join in Renée for and disclosure Kim to these Vice from Vice materially for differ in and those today's review you or differ results Officer; related our undertake expectations documents, performance those Executive XXXX performance the and from the release, growth Manager, contained the statements We General President; today's results and America, obligation and actual President our press team today's Sablich, and latest contained On such cause and update SEC could on encourage related of and forward-looking which deck in R&D. that forward-looking Global I'll duty Q&A. forward-looking goals, Executive actual operating as Chairman our will future and contained company's XXXX, slide in Rob X, On financial President our Vice Financial President, Vision results, anticipated to and webcast and Slide

to non-GAAP of Bruce. on Investors now non-GAAP in included the we'll in measures. today's X, section financial to and website. financial to press available webcast, GAAP are our Slide on presentation this over release I'll Reconciliations call of discuss Turning measures slide the turn the

Bruce Cozadd

fourth and a commercial, Thanks, to you Jazz consistent Slide strong diversified, for substantial I'll a we throughout and thank XXXX development overall XXXX, company. on transformative our today. with quarter continuing biopharmaceutical Beginning the start made X. global R&D everyone, for execution. evolution financial progress was performance Andrea. Good joining year performance. In afternoon, and with us innovative XXXX corporate our across and

delivering billion exceeded call. our financial on income line basis. range we performance the top billion of upper of results will the Renée detail at non-GAAP a end revenue later nearly annual time, For and in first net the in more adjusted guidance $X recorded $X in discuss our

portfolio. by concept driven or met and Two target were results launches, to line our across hypersomnia, execution are top idiopathic of exceptional in Jazz our XXXX X that of ambitious Our Rylaze We XXXX. acquisition, commercial Pharmaceuticals Xywav products. Epidiolex XXXX therapies strong in in and commercialization. key advanced product commercial IH, to from revenue from those are track portfolio, net diversified and Coupled approved XX% coming of to least goal or newly on addition sales GW our the have we with our of at the significantly acquired of launches through our meet

ALL of August approval respectively. June and FDA secured we side, XXXX, regulatory for and in for IH Xywav the and in Rylaze On the treatment

for a of Xywav Xywav from received the as in clinical for orphan drug also lower FDA for Xywav therapy in We drug received FDA compared IH. to benefits orphan Subsequently, oxybate sodium with June Xyrem. narcolepsy we citing exclusivity exclusivity

milestones, trials. commercial the candidates active in to we results, in continue the with clinical regimen sBLA important advance year, concert U.S. studied of January support an this we strong R&D novel in regulatory XX XX pipeline, In dosing comprises which addition, now submitted to updated being delivering Rylaze for and our In achieving

initiated On in JZPXXX stress we and important programs essential the Phase for X neuroscience for in trials post-traumatic side, clinical tremor disorder. beginning X JZPXXX in suvecaltamide, or XXXX,

our The in growth the initiated in Pharmaceuticals. cultural Phase integration third acquisition fit X Jazz R&D We was existing The industry-leading of we cancer. nabiximols to milestone teams. growth is and of maintenance is trial by our the past, in cannabinoid the a the the in And acquisition therapy proceeded the Tecentriq development our small as to XXXX combination as complementary in has well. a there ongoing of highly as platform contributed of multiple Roche, also part GW lung And related evaluating GW initiation Zepzelca in has GW exceptionally headlined first-line sclerosis that Phase to partner, with commercial A trial noted X I've added noteworthy clinical collaboration our oncology, a in robust Zepzelca have extensive-stage our proving for pipeline. portfolio with be GW and spasticity. effort to cell superb between

talented positions for exciting enterprise. year thrilled These ahead. all of accomplishments, have and GW our of team which were across and strong cash an Just flow the set allocation experienced the are by capital combined that many members important, of underpinned as we're stage strategic in leadership

differentiated At executing deliver on that which vision. several On XXXX, out this strategy Vision continue therapies Slide portfolio to and on we've that high-value to pipeline Conference and clinical will JPMorgan growth X, a commercial introduced the of we operational called sustainable included us value components. We drivers stage believe and enable upcoming Healthcare this we January, enhanced deliver be commercial our to build laser-focused value.

this the excellence, the advancing and half and goal advancing will multiple across X.Xx oncology we and launches, respect global net of focus of operational of pipeline, than Rylaze first data first leverage neuroscience by in For strong momentum Zepzelca clinical less we XXXX. continue Xywav, and continuing to programs the With we Epidiolex our and and in execution our portfolios, on our U.S. markets. achieving of well mid- focused year, late-stage are of including as program our nabiximols the end as are including to our commercial, maintaining growth the the anticipate from on

Vision to in the strive need. frame years X. our innovative patients will and next Turning therapies several business to bring we to as Slide XXXX critical for new

As I core there are noted, X components operational vision: our and to excellence. pipeline commercial,

positioned First, $X achieving in billion we're over XXXX, billion revenue commercial. After in in to XXXX. grow $X revenue to

anticipated contributions revenue to commercial development strategic products and from as as transactions. existing products expect sales of growth as products corporate generate expect candidates that portfolio acquire We includes and as in $X geographic expansion. billion advance pipeline to through from to well The we that our we may realized current well market organic also indication

patient pipeline. decade. novel in In foundation of needs advanced neuroscience critical With least our product key significant of a solid by areas unmet addressing the in will programs market organization R&D place, Second, significant and approvals need opportunity in at we and X believe oncology. XXXX, our the deliver we end

about addition through in pipeline, platform, assets continuing legacy GW excited programs we're In novel opportunities. the and and corporate cannabinoid emerging promising compounds oncology and to neuroscience pursue potential from our development are to evaluate we

excellence. operational Finally,

by we XXXX X adjusted more top improve plan to line margin was margin to Our operating of delivering adjusted and bottom XXXX, XX%, XXXX our line. through percentage the to operating points from our

Q&A. cover provide And gives achieve will Renée of Our is over of Vision will to confidence in Dan? execution our our the line which XXXX call ability us our Dan after our open accomplishments for to track record XXXX. programs. to I'll progress which vision. overview of this strong in Renée update on will shortly, now R&D and guidance, performance, we'll and overview, Rob turn a an commercial then share call an the financial with

Daniel Swisher

commercial across Thanks, continued Bruce. Well, to the portfolio. I'm excited share progress our

to launch to in to deliver narcolepsy as neuroscience, approximate us need. this fourth an therapy of XX,XXX with XXXX, in significant to highlighted continue last enabling compared Average the we our Slide patients to increase build quarter, starting another Xywav on X% year. in patient This the franchise of includes oxybate period Xywav population with in same IH approximately the and and market-leading increased momentum active November important So X. adoption oxybate commercial

the Xywav an with and sodium patients sodium with care a With We in physicians patient and live its exceptional of educating adoption. active increased in patients cardiovascular of we high narcolepsy. with introduction we meaningfully burden lifelong with of X,XXX with product comorbidities. and year with the patients lowering on across XXXX lower population strongly The a in benefits narcolepsy in risk pleased narcolepsy and resonating focused exited late Xywav who are intake oxybate remain this advance intake patient approximately are prescribers, sodium of

prescribers We've impressed received with bring reports the of have only are been on Based been from the and the that launch field, providers adults to IH just with IH began FDA-approved momentum have of option treatment addresses Health November by to IH feedback profile a in IH excited patients. launch this care from excited community. treatment we've not and for positive commercial we're the X, its medicine. symptoms. and the prescribers and first the to early Our Xywav encouraged XXXX, in

IH also and and time to in has have will coverage that and for faster similar occur and We covered. to narcolepsy patients. prescribers narcolepsy approximately or of IH Importantly, currently expect have pleased been access coverage XX% anticipate similar Xywav lives initial of Xywav commercial Xywav frame. with their the this a

include IH. IH, commercial to patients the XXX While with this we're of continue of update percentage Exiting approved active launch. payers there to see phase encouraged originally claims their policies higher than were anticipated approximately during to Xywav a quarter,

new the While represents where Unlike IH no significant in there Xywav. with and growth of approved still with cadence therapies. of launch to both positive patients have health starts the the a over disease a there early experienced be recent in we're a IH from that in more rare where line professionals narcolepsy, of for number launch driver oxybate significant transitioning IH pleased expect we feedback Xywav been was patient launch, to the care previously patients.

market, and care. diagnosed us a to actively existing IH with patients XX,XXX is Our diagnosed driving actively the awareness people patient Expanding with longer-term market health the are XX,XXX focus prescribers the we are XX,XXX IH patients. diagnosed seeking that adoption and beyond approximately total approximately initial treatment among narcolepsy that likely who diagnosed IH opportunity on is growth oxybate seeking which as estimate to is close the provides population

Slide forma to revenue temporary quarter, XX. levels. same in fourth sales the product basis. specialty compared Epidiolex, XXXX period benefited saw on a to In XX% Turning inventory in in the fourth Epidiolex growth net a we quarter pharmacy from In the pro increase

where a initiatives effect, to third markets. full international XXXX HCP and commercial on COVID-XX, able that XXXX a to pleased surges hybrid with compared our growth robust revenue sequential inventory versus Excluding on in revenue XXXX the basis In we was of were pro XX% have quarter U.S. engagement impacted seen non-personal fourth engagement. both growth We've this increased quarter and in adapt how U.S. full to includes engage changed how virtual year normal continues this is promotion and year of challenges achieve access a care the that to industry first year pandemic, we the of to patients. and with by our the has have which more environment, engages high of forma COVID-XX providers. new we customers to were the basis. -- XX% with with their new our customers adjusted health level Despite of a

growth, prescribers addition strong add base. prescriber to In continue and we to new Epidiolex' grow revenue active

the gain prescribers within therapeutic its adoption. new experience this and to as that benefits will continued of contribute of practices, broaden use Epidiolex understanding expect their and We

strengthen As to potential. was of want new Epidiolex. also December, IP that this a issued momentum, the in preparation listed patent blockbuster covering build patent In we Book botanically using highlight to we durability of This FDA XXXX. the medicine's in the confident used underlying drivers that growth to I continue continue disorders Epidiolex the the CBD and Orange composition U.S. derived in extends indicated through treatment preparation. CBD of now remain

We are significant make also to progress in Europe. continuing

launched Switzerland January most we with launch Epidiolex Spain in quarter, this in Italy, and Ireland year. our of successfully recent third the in During

to to later France XXXX a our and -- XXXX. will be Epidiolex about pricing, in be access all which launch future major excited contributor year, point, reimbursement pending Overall, Vision markets. to final discussions, X European of at expect significant the in as Epidiolex and reimbursed this growth we addition, continue top line In and we potential both in launched would

based on and profile therapies. growth steady algorithm we feedback with the be as standard of as in the combined in real-world settings Even use and efficacy treatment unique we're mechanism the the increasing confident safety challenges We ability earlier action, its other brand. treatment-resistant of we achieve in The and pandemic, positive epilepsies. navigate remain Epidiolex can by blockbuster for are customer positive experiences status of to and encouraged of the care the

on moving now to net XXXX. XX, the and oncology strong for quarter growth compared Slide with are So $XX.X million, Zepzelca see with Zepzelca for we the same to starting of continuing XX% in period revenue fourth demand to

will We with in have this Zepzelca patients as monotherapy. our lung products development as cancer plan established cell cover Within evaluate small second-line who treatment immuno-oncology choice can topotecan which therapy, of to a of lung small growth we Rob displace see depth. benefit indication to current more cancer, and used robust continuing opportunities second-line have additional for steps the and in being from in place cell

and Zepzelca or use additional clinical trial setting chemotherapies We pivotal chemotherapy also ongoing in among Phase trial provide this patients from receiving regimens. data Zepzelca other support population. see potential Findings patient this rechallenged the our X on in will with platinum-based being

launched our the Fourth net Turning to July recombinant were product $XX quarter erwinia quarter market therapy full Slide million. XX. the We Rylaze, first on in which asparaginase was XXXX. sales,

continue on ease commentary and the with We suite of feedback support well dose as from our services. ordering as customers both preparation encouraging receive to of

notable discussed among 'XX brand have available the Fourth hypersensitivity performance asparaginase. U.S. was we Rylaze only in uptick of supply its position the Rylaze and patients quarter as to As who revenues a increased awareness reaction for strong as a reflecting therapy E. in previously, remaining market showed beginning was to coli-derived Erwinaze orders in depleted. the customers September there in

Friday XXXX inventory, We pleased to which new We're we're to excited of typical the in also update buildup cover and detail. to an very is our saw more will products. Rob the date, expect launch Wednesday, which initial strong potential messaging label for evolve based with Monday, a launch on in dosing, performance

execution in results team XXXX, our across our portfolio. summary, strong and So commercial delivered driven by in successful launches

call the for our to milestones pipeline discuss in Now successes I'll near-term XXXX, turn R&D Rob? anticipated over to opportunities and Rob XXXX.

Robert Iannone

including approval. XX, accomplishments XXXX efforts, Slide trials very stress compounds in in on for initiated a brought X these JZPXXX both ALL and tremor going for were acquired milestones. detailed in We focus clinical and On received We we've JZPXXX Suvecaltamide for today's our the to therapies. programs from which few mid- build our X Dan. of FDA we Xywav to IH, in for in development data I'm a R&D corporate It year On concept productive for existing essential or disorder. to Thanks, XXXX organization. trials, and Rylaze recap and team the is late-stage multiple clinical promising Phase and then pipeline. call, excited for clinical our key approvals these upon post-traumatic Both through of was

than drug acquisition the expertise pipeline, in group in of number development between to GW could has and and our addition, XXXX has program and deep and Pharmaceuticals And exciting talented has us a our R&D The better have In integration professionals combined progressed cannabinoid of milestones predicted. programs even preclinical added the GW in we organizations ahead GW of platform space. cannabinoid many Jazz industry-leading with clinical the beyond.

combination Phase are We in initiated advancing cancer noted partner, being second-line cell and cell Roche, trial own Jazz X evaluate observational our separate by XXXX: cancer; Zepzelca earlier. trial in post-marketing development lung for and trial small cell PharmaMar; lung confirmatory in small that a robust small by Zepzelca. with partner, run Dan a trials cancer to effort lung X in our second-line extensive-stage in also first-line a supported our Three Phase were Tecentriq

basket our as this Zepzelca new several X in Phase a earlier is evaluating need trial area types. our addition, have initiated where tumor solid monotherapy movement focus for year, significant to disorders deliver potential of and particular treatment One therapies. of unmet team the In there we is

approved up Spasticity, the no which options. occurs Our nabiximols limited need, in trials major the active related anti-spasticity with in to treatment new years. spasticity. the critical programs MS oral now issue have of Despite medicines has XX on patients, XX% last U.S. is sclerosis been in multiple X a focused

first expect which trial, If modified in data using the from is to half results for in X submission change first relative year. XXXX. and potential a regulatory from elements this muscle tone trial Ashworth the of shorter We the later our trial smaller others is This this is of scale. are there positive, assessing the U.S. in

read larger sizes X in have from data expect to late We and which XXXX sample additional early trials, XXXX. out

oncology for label intramuscular patients milligrams on As dosing per Currently, our of the submitted under and with Wednesday, our XX squared Friday receiving the review Wednesday, Dan Similar milligrams reviewed update mentioned an Monday also support to administration BLA, and earlier, the hours schedule to meter XX have to sBLA per an Monday, we XX sBLA schedule administration application IV of XX meter squared. mid-XXXX. later Friday. treatment. this maintain the current process. dosing both to to to through practice will well as square planning patients original more schedule, with weekend and clinically meaningful another is as in duration on review Europe year labeled entire in every meter serum the to a This dosing in also FDA level activity real-time regulatory milligrams is allows avoid be of IM line for We're per application to which intravenous clinical an asparaginase Rylaze

Renée a will Renée? off I Now financial for to Renee pass the update. call

Renée Galá

XX. Slide on begin I'll Rob. Thanks,

business significant positive momentum We the XXXX. entering throughout finished in with our year strides have transforming we made XXXX and

guidance. noted, of achieved total our as our guidance top end neuroscience Bruce revenue as As XXXX oncology the we and well

to delivering XXXX. to than included $XXX oncology XX% billion $X.X revenues of and $X.X respectively, XX% represented with This both compared growth billion XXXX. neuroscience compared more revenues and of franchises million, XXXX total Our of growth

expense. Turning to operating

was year Our GW driven revenues, and R&D while pipeline income trials increased XXXX the the capital adjusted with addition focus the pipeline from of increase and EPS Through expense in SG&A significant bottom to approach generate our the reflects which product mid- initiation drove platform. percentage XXXX multiple strategic This launches. and to a launches, ability by revenues, commercial and clinical to expense M&A, and strategic XX% late-stage adjusted of adjusted X are adjusted disciplined total transformative investments across reflecting of XXXX investments XX% of point multiple cannabinoid respectively, our compared top and growth $X revenue to on XXXX. line billion in both our we XX%, full allocation. net in of expansion demonstrating and ANI nearly remaining XX%

Turning to Slide XX.

Our positions us XXXX. strong XXXX in performance continued for in growth

line, guidance XXXX oncology $X.XX is This by total top approximately midpoint, for both the franchises. year-over-year On our growth the range billion driven revenue represents neuroscience XX% to $X.XX our and billion. at

neuroscience, compared net growth For billion sales billion, of XXXX. our XX% midpoint at to guidance $X.XX representing $X.XX the is to

opportunity in Our conviction confidence guidance our Epidiolex reflects of the for oxybate in the durability growth and further franchise.

guidance Our to compared XX% is million the midpoint of to growth oncology XXXX. $XXX at $XXX representing net million,

towards both capabilities. a aligned Our our our we're lung significant Vision excited execution Rylaze, treatment to as XXXX, by have to oncology $X of second-line grow cancer which franchise of continues demonstrate for business the cell commercial and billion-plus and demand to established being choice the rapidly small Zepzelca

revenue our at guidance On non-GAAP is approximately billion Turning million $XXX our XX% a to to XX% to SG&A our is at midpoint. or $XXX of $X.XX revenue our R&D And approximately billion basis, OpEx. midpoint. of guidance $X.XX million,

corporate does any expense guidance our business or advancing on guidance I our optimizing would note focus and continued our reflects driving growth, transactions. new operations. sustainable pipeline include development not Our revenue

be do this expect active in across to we area However, XXXX.

underlying compared which With at net represents margin improvement from improve income line important important in gaining target continued reflecting We our $X.X our towards I'd midpoint effectively of to adjusted adjusted scale like point assumptions our XX% are our guidance. product growth XXXX bottom multiple focus feel improved XXXX, of our to our XXXX Vision operations to note and to confident launches to X billion non-GAAP driving commitment the $X.XX excellence. delivering a on XXXX. operating momentum, we increase ability several XXXX our and achieving billion, projecting percentage operational a to underway and

with guidance neuroscience First, to our Xyrem respect and generics. authorized

under XXXX, first slated is January launch X, The circumstances. earlier for or certain AG

the our direct of strong AG accounting oxybate which continued other in XXXX. launch second do XXXX. the sales, and before We AG Given XXXX. Even of for entry the of continue entry has of reducing for in future the of competition, choice Xywav, potential anticipate we AG guidance Xywav half effect entry expect potential not to the be half the oxybate to therapy assumes Xyrem second

our Hikma are AG first following allowed is As the they relevant Hikma guidance. and onto components a volume the reminder, neuroscience are unlimited. to royalty market, The

AG to of AG. oxybate royalty Xyrem ranging, Jazz XX% and the volume is sold starting term, X volume total of paid at and on a the Xywav, months first rate AG total XX% Xyrem During of wide the and based units units percentage total to AG as tiered to the referring that going with

XX% where approximately AG to to in During EPS years in in for change period. of fixed adjusted our double shares X $X million of XXXX we per at the a AG the important growth considerably EPS. midpoint. we substantial guidance. have full under each EPS in non-GAAP new XXXX X our for for rate With regardless accounting the economics be beginning the of high EPS Hikma the the include beyond convertible rate fixed calculating our to increase is our to this adjusted convertible the share change results share X XXXX guidance, Adjusting then Jazz our note that Hikma respect royalty second debt AG This dilution in a implies extended Should results of higher at will volumes. the accounting the approximately our part instruments debt, Jazz rate of will the the X-month rate term count for XXXX, underlying as period, accounting standard remaining year, digits paid and would to royalty become it

XX. Slide Turning to

enabling business flow drive to to well cash enhanced are value strategically in objectives. on strong as as invest disciplined and sustainable our growth and near-term allocation deliver our Our financial us capital

on significantly following have with generated the diversification fourth our in acquired nearly our us X.Xx delivered results ratio and of we And XX% the end stated top XXXX and bottom by back our significant non-GAAP of achieve of Vision below or quarter growth sales this well of full revenue deliver keeping targets. leverage line reduced financial to just We us products track to in positioning are to track to by being our the in now from In end since launched on XXXX. of the XXXX GW advanced to X.Xx our on net meet target X expect diversification the target at XXXX we close net XX% to a of we the turn XXXX. turn year. In I'd like months strong the Bruce. XXXX, approximately product summary, call acquisition, in

Bruce Cozadd

our business most and notably IH, achieved X goal key and and was Pharmaceuticals. Thanks, achieved of year approval the transformation expanded on FDA X in with to execution. Rylaze Xywav and Slide years. conclude for executed we of key growth and revenue XXXX of our Renée. prepared acquisition We our double-digit transactions expertise GW our launches of XX. ambitious I'll a And remarks pipeline capabilities, grow

an IH. and to with refractory Zepzelca. addition The the with opportunity our Xywav continue of teams demonstrated on portfolio we Epidiolex commercial for of that provides deliver will the successful Xywav important to Rylaze therapy Our of launches execution narcolepsy And for us the epilepsies. commercial and to with patients expect performance strong launches

is organization next products R&D and deliver late-stage its Our expanding to important are capabilities. initiate underway, over for multiple XX we clinical continues are additional trials Trials mid- planning the and to months. and

clear a XXXX. forward, Vision have Looking we map with road

the progress optimistic for we line look the the excited about on we're prepared the the year We operator like That forward over to concludes call and you to turn and I'd open ahead, We're advance. our business. now Q&A. as delivering across to to updating on remarks. our our are future, focused about I

Operator

Instructions]. [Operator

Ken Cacciatore comes question and Company. with from first Our Cowen

Kenneth Cacciatore

Kim, and to just Xywav all Bruce the progress. Hey, congratulations on I ask IH. wanted in about

that and in as clinical IH they believe narcolepsy. could be big indicates recent Our in survey Xywav as Xyrem work

internal IH could if share And that, little put to your wondering Xywav. the a your mentioned know in you on potential for categorized Dan, And your an you if then, the but the of kind same orphan eventual at Can you of So as more data. wondering look more little frame even expectations, hopes you markets bit try I size, granularity a next years? could, the like could you out that bit we Xywav launch. few for

Bruce Cozadd

Yes, the similarities couple there that narcolepsy I'll questions. people and and And start for remind just we for maybe idiopathic a Ken, thanks of are hypersomnia. about as Xywav think Xywav for

these and effective right, their that to is very ability patients These debilitating of disorders, reduce function. find improve to first their sleep of are The treatments, remember that right? high life-altering both to really symptoms conditions, level are motivated disability and are really

cases. is need both So in high

remind a of The in seen of the second agent these both in we've similarity conditions. you terms efficacy is thing I'd excellent

patients. strong of in data terms the Our to very X Phase were provided benefit

So we start those with similarities.

that specific of to maybe data, opportunity As we Kim ask for I'll of where on that. Kim? in get and comment size the front us the

Kim Sablich

Yes. Sure.

November, reports address, Dan on clinical of the from build. or compelling prescribers impressed that condition the saying option trial with to with IH a and treatment profile by symptoms. X really positive the not momentum very results large. just at began start have have that the I'll the we're as X So since our been the medicine, said, back full a especially and positive to excited seeing its very we of launch the encouraged from Based field by continuing are that feedback IH prescribers in And and community

communicating the that actively on do XX,XXX total XX,XXX is data diagnosed of based term, patient market, be to are that the our to of been we've IH the been existing opportunity, patients. XX,XXX on estimate call patients size the longer -- approximately narcolepsy of health with data seeking we terms diagnosed claims to the But care. outset have IH In diagnosed we closer launch focusing which at is and adult about our likely sleep that who universe are population

for milestone approval is this a Jazz. So significant for us

this our a to build that here launch see marketplace as throughout of execution feeling are of recognition launch with the a franchise we market-leading to oxybate we already to pillar As on continues continue in going successful rest we're be starting and Jazz's in it we're brand the of that IH narcolepsy to value, valuated year.

Bruce Cozadd

Dan?

Daniel Swisher

this We're only Xyrem It's to orexin first to side, Bruce. a narcolepsy. similar therapy go is coming building in Ken, just IH. approved sorry, and on kind Yes, -- into And market. yes, it's a Ken, the of new

so REM patients to efficacious diagnosed, Xywav, an them are them them system, while to up the familiar with cadence is And dose the the into dose. get get

So this oxybate experience can convert of there's pool over. existing not we that patients immediately

encouraged build level Kim experiences of high seeing quarters. date, we the we're as So we're look and to coming forward and saying cadence on to awareness the is by that in

Operator

from question Fye Our JPMorgan. next with comes Jessica

Jessica Fye

Rylaze should looks XQ the It rate? off that How we like run think the trajectory our of in quarter. above expectation product this came well about of

Bruce Cozadd

option on were treat it. patients ALL the question. the desperate how Yes, sort calendar when market year treatment and performed would always for in our good to reliable full -- its Jess, has Rylaze there really docs who a with first have pleased calendar these that the pediatric of made We ordered they were thesis full be on thanks quarter that

quarter bit on results. and our early So I the trajectory fourth can on the a comment let launch Kim little thoughts maybe

Kim Sablich

Sure.

and the of supply. Feedback XXXX profile that typical that on brand some part strong I'll strong the we Rylaze positive positive Rylaze following depletion is the say, But therapy for and performance of Rylaze. And the initial demand reflect among and reflects for clinicians customers and quality as we've inventory increased supply available our around well the products. as for been appreciation and as in Erwinaze ordering and really strong quite awareness of revolves the preparation ease our marketplace which Rylaze. only product build dose recognition is revenues, the for reliable from launch, So new high has received really saw we of the reports believe both both

of a commercial strategy does our date. recombinant for overall, advance starting of the clinically are we recognize and launch I'll significant and meaningful account activity that. Rylaze think market. asparaginase and the that So erwinia very we to a is appreciate that manufactured But product as for overall, the represents believe really duration And maintains only prepared with through we're asparaginase entire treatment, a customers clinically pleased competitive to say level

Bruce Cozadd

just not Rob, done we're with you Yes, might going because to comment on where our to we're Rylaze. strategy want on

Robert Iannone

Yes, Bruce. happy to,

indication for which So on is ongoing as XX know, our hours you based Rylaze. an of was every now, trial

real-time the that and We'll data as which were to where and in dosing, X-day for XX also And much with twice Friday a optimal ensure in sBLA so granted the but we through that IM we Friday evaluated Wednesday, that we We've milligrams squared an IV with coverage follow on FDA give as a on regimen to Friday. with that IM weekend supplement meter well. as as submitted oncology U.S., also allows underway. Monday, is review, IV Europe the per and the

Operator

Our next Akash question with comes Jefferies. from Tewari

Akash Tewari

contributes the of million or about get CAGR. $XXX in as Epidiolex looks you XXXX that assume for in guidance, neuro like from as it neuro at did your an XXXX, grow implied did same sales we sales perspective. XX% X% to franchise only That your for XXXX, needs about it pro to it growth of hit we percent a forma year-over-year said, If

Additionally, comment like guided? in XXXX ended GW what XXXX? looks growth drive what Epidiolex you can if Epidiolex being as accretive on previously And you post So in can inflection growth long an comment would up term?

Bruce Cozadd

Yes.

over So growth you pharmacy in the really out with the piece sequentially of quarter; still sales, then, that. XX% how fourth even quarter up jump up We a let can accretion. level, third at basis the maybe were in me Epidiolex quarter, start Epidiolex forma annual year at factoring performed on if pleased looking and And the fourth of first with XX%. EPS a reported on we up inventories had higher pro full as Renée,

we're out, remember, to in that process ex-U.S. pricing also both in out rolled So roll we're it the market. continuing growth, And Epidiolex' continued we're early excited reimbursement. where about in and we still have even markets it more with But launch excellent U.S.

the we continued see we given breakdown years, So of -- Renée? we but with a specific growth further of in expect upcoming a each haven't opportunity substantial breakdown Epidiolex. what

Renée Galá

Bruce. Thanks, Yes.

and in of expected underpinning that we stated be XXXX in state the to to did shares continue thereafter. in our GW that accretive accretive that's have year, first underlying do convertibles our by We note, GW XXXX to explained million that approximately also in however, our shares. increases the do expect the So accounting calendar substantially X accretive transaction yes, the increasing in so I'll as I And used be full shares change we our that I we transaction the EPS the XXXX with -- call. in remarks, guidance prepared impact are the an XXXX. has as

Operator

Goodman next Leerink. Our with SVB Marc from question comes

Marc Goodman

a about question. new you thinking you inventory view in we run this us said this build we talk Should Can the the can quarter And you we Epidiolex should understand a we about run is how think in inventory there. and be how patent? of some the that there, You this should rate? that the just patent what Rylaze was underlying can help there was new was follow-up much quarter. real Bruce, rate understand then think Yes. demand kind so how on

Bruce Cozadd

the for question. Yes, Marc, thanks

that Epidiolex. to time going one is Book. the IP XXXX. Orange believe we of you, prior estate its about the a on the in is this significant disorders, our has On out derived patent part durability use established and different this and is This meaning date expiration a remind patent, composition are I'll to treating of relevant that a certain those patents listed in in of botanically from thinking over CBD label

included year. So in was very end the at patent XXXX this Book pleased the that, and Orange that tail of earlier issued

with Rob they've stock with quality, That's immediately it Rylaze But excited couple available. over had and a more a stable to use one to time of And people that can use see want the product also their for available, now asset. modern Ideal we're launch higher surprised of available. of not manufactured And some the Before true we're that the constrained try been supply of people of that really means. as they all to past can durable because substantial people access available the be to Friday the product this in that rather right? submitting would past, most minimize puzzle delay option is other appropriate it have around get by for than Monday, fact use So piece then be about a why say supply what Epidiolex more with get premedication Rylaze, there's rate in run some have high that not erwinia-derived expand know luxury more always confident the just in I'll a asparaginase we've the buildup Europe. to we to don't on did then to Wednesday, cases, trying Rylaze, it's now and obviously fact are trying as clinicians, the product the or level. that supply just in also I'm Rylaze to years. need. use as used to then patients agent And patients a And adjusted use to adjusting an is or in save in ideal to giving not well. at IV practice talked we dosing

a which us. back opportunity of So U.S. we today, worldwide just product, a to for more go having is

for what rate So accurate lots view with that response, the will of we us. progress be but not don't a pleased more run just more initial have Could ahead of a of be. basis Marc

Operator

with from Our America. Jason next question of Gerberry Bank comes

Jason Gerberry

request, just you calls, could from Bruce, in be future that earnings pick structure settlement great. would a that in slide a a put if

growing the filing. showed this this the terms might includes my we'll I guidance whether patent a in So updated. year are the monkeys, capability has to amounts on ground, is synergism with guess, questions TSC, that feet your versus this for on compositions I generic is the synthetical. thoughts think, so understanding, someone we of challenge then have synthetic And of IP Epidiolex, oxybate that, trace XXXX? benefit And in schematic that believe or a patent requirements the But FDA which update, with have of my I in whether some get just expense.

Bruce Cozadd

Yes.

that on Obviously, it Jason, the We weeks terms results. thanks On use. oxybate oxybate, narcolepsy. our in IH royalty see suggestion launch grow So is for of new, fourth quarter in structure. we're brand to continuing the just into

do growth we expect year. substantial the during So

as an have do our the in economics we launch we guidance, room assumed in that, made generic. our while of that economics current As have of do guidance authorized for we've And second said we half an in Xyrem don't XXX% we in product.

complete but to whole with growth market, Jazz. it's in revenue the not So pull-through

that going that's so seeing what think we how about And you're and forward.

number. think If we of patent terms we it. can Epidiolex, we give In the gave didn't, I

know. could. in the again, not So of do we've challenge, Whether to course, early see will cannabidiol. And there, there's confident believe and that's you as relevance composition patent completely and of included opportunity that can that don't look we to for people up in feel this But year. happen, we submit protection of got potential that product. step as largely good product, the everything that which there's we but entire is It later terms that but of

Operator

Needham. Our with Fadia question Ami next from comes

Ami Fadia

and X had main X follow-up. I

Rylaze. on for in about terms hypersomnia. expect quarter. saw fourth regards Is the of to upcoming young quarters? beyond should about you we some precedent the teenagers the in just give secondly, type How with And Just utilization think that? We that into Xywav on that the XXX new saw with or whether a us you adds cadence patient patients Can pediatric about to then of color regards adults? you in indication

Bruce Cozadd

Yes.

been drug marketed remind launch in in IH, early we're Xywav just happened on I'll There's hypersomnia. never right? November. This a idiopathic So just launch, in super you, that

the adds the reaction same paid has the which only quarter-by-quarter what early of the probably the same patient bit a exactly drug, So cadence new of idiopathic we're for us on predict that hypersomnia. premature. a to is will we're excited the after Again, size The the of months the couple drug opportunity, get of excellent. calling be effectiveness for to hearing, about little the prescribers for, the we're narcolepsy largely been -- and ability fact super

early particular too treatment, to but be this physicians new effective of to predicting and So about we've educate got availability patients the our ramp. do continue work and to to a

Rylaze pediatric, share let beyond she'd terms Kim information if ask to there. In and has of she utilization any like me

Kim Sablich

we notion the asparaginase type, marketplace. to market than go we when line or any age the some by patient and that constrained. second had the faster to overall positive seeing of feedback specifically really No, don't are supply start data And have Rylaze they in the just utilize customers was

Bruce Cozadd

our turned which remind can E. in young response patients create we adolescent and ethical to I'll promoting believe didn't appropriate demand use get who things Yes, asparaginase, just we one are We promotional of because years certainly hypersensitivity of include approval the as this well. coli-derived efforts it for is would experiencing patients be several back our adult about of product, off great also the mind we to that all Rylaze to pediatric but to people that the includes the couldn't supply. try

regimen pediatric-inspired efficacy. We be as enzyme asparaginase was And that then where an strategy, an the silent again, counting we go you in regimen adequate to patients. that the never markets see very creating have antibody we people the the pursue opportunity data of that you're where time, make over broaden an commercialized So can to containing you you're on out inactivating registration Erwinaze may for now of because ex-U.S. kind response also supply. and remind inactivation AYA do lack sure use of of when a understand people for

we utilization. saw opportunity do fourth really to there's believe that data going have forward quarter. the as But on says, increase we So in Kim we don't an specific what

Operator

comes Ronny next question from Our with Bernstein. Gal

Aaron Gal

if mind. Two don't you

expect realize how clinical rebate on long end price many if the numbers of of both given the you kind with in many idiopathic the hypersomnia. those first. of the other do First, get XXX program? those at initial with just And end patients have adoption? the that you year, to for get up could of in patient of wonder on on couple a us structures? a of Epidiolex what How share I increase patients for oxybate how drug. of that feel Roughly, the kind picking And hand, early to increases could of saw that around get the actually were in we patients percentage the the to pipeline on trial had and price drug year it better the XXX the you takes separately, in trying given so that

Bruce Cozadd

was co-processing. that Ronny, question Remind the product end me I you were the at price increase? with which of about talking

Aaron Gal

Oxybate and Epidiolex?

Bruce Cozadd

Yes.

Okay.

the we contributor We we've of So on at that, to of Not the the of more going a up process end a data, We sure don't first, that process came out getting starts how in the starting know many that early we patients jump REMS significant actually sometimes if year. the heard enrolling the ends I've shipment from drug not give in, of clinical have patients than the patients get team drug. not count a Ronny, already for sort given somebody was the to as adoption. they drugs. REMS. I'm shipment of on the in know trial. everyone We're until of those of our terms patients

that price given our So we've the bottom not do does on but net down around increase, be recent flow that the sales particularly in oxybate, in all gross sure price would benefit. contracted, information. way not And realized some line accurate years increase we receive

don't increase. realize meaningful gross assume price certainly think I a we but we historically, percentage, said that it's of the all

Operator

Barclays. with Prasad Our next question comes Balaji from

Balaji Prasad

me. couple A Congratulations. of questions from

now? an had what in Texas respect give you could till with previous Can there patient you're GW a versus with planning so -- And decision Epidiolex, the acuity the Epidiolex, on Canopy's litigation. litigation. called has dynamics Firstly, the on out you from be or seems update to tort Canopy seeing court visits current the with the QX the secondly, court quarter. you as on in visits challenges to to And

Is challenges? So there does of? not this settle all existing aware we're legal anything else

Bruce Cozadd

of terms on pediatric side? the to epilepsy about want you Dan, we're in what talk seeing visits

Daniel Swisher

and customer saw in they folks us don't open. the were infected engagement closed that where have -- any offices things, definitely our out impact were of the I also been numbers, temporarily locations side well, getting and been service of there's were of certain typically on as some even definitely have but and continued was exact Yes, with Omicron, offices

it the think does good to be down and rapidly. news it early -- peaks seem I is comes

be a And into year of patients fairly optimistic for in back at offices will the the flowing cadence. so our normal the is more expectation that rest

think I of is, And vaccines X. slower with not exception again, but are getting percentage direction. under our they're one those vaccination again, regular under a the children are the that trends for the -- X. are right number or it's a patients in the But available. vaccinated, we going lower the therapy, And who rates have and than for the at XX percentage Currently, between population. at than a still are X

Bruce Cozadd

but the then to out with court pleased litigation Canopy. And judgment the the the right side, on do certainly They with litigation where were appeal in with came on the that, but have final we pleased stand. we're we been where not interested the case. if concerned and that sure not have had significantly It's I'm And we've there's other other remains we something litigation about, particularly some litigation. you're in, been

Operator

with Stifel. Our Samimy next from comes question Annabel

Annabel Samimy

color back going Epidiolex there. Just bit hoping more get to to a little and

there's cut some some still is mentioned So talk inventory. where heard from indications? Is know have I but treatment? patients? is win you're new new that quarter, maybe you penetration? high. most it that persistence it XX%, KOLs excluding as primarily seeing can And We in that of Is the the obviously, persistence you the the I headwinds, you not guess, COVID it about Or this

you're the as where in as So persistence there from? can well that coming new what work us patients of terms tell you doing are

Bruce Cozadd

to Yes. information that's new the me. Annabel,

really up be to most the of multiple in to treated we've And of remembering continue exceptionally agents remains new the the want combination. think still patients the tend added to time We one data with Chicago as agents, we add about it's of hang of seeing to December, going we regimen. later multiple these of anything out things pleased you'll how believe sub hallmarks they treatment terms they of AEs into on that to there case KOLs years it, be they out noted they what Epidiolex when some in in talk the drug presented And of and that continued we're before, the in and we over often with to early was efficacy use that and to agent. are see this that one increasing is persistence, at meeting went a in Epidiolex cases, if

surprised goes does or Kim of I'd you hear data in be that we're in So seeing Dan, the one to other want direction. in jump of where terms to growth indications? on

Kim Sablich

on coming everywhere. from do the basically largest I'll LGS We're growth, room we but indications, in to numbers we believe, still X see anti-seizure a opportunity and remember that treatment sure. growth for are launch growth the phase. polypharmacy of TSC, important that, to as indications, that is well-tolerated specific across is medication. greatest say in It's all setting. penetration which this can high average, with sharing particularly early said, a patients our the And Yes, Bruce continue added is not in on the treatment-resistant persistency, be X

more it that are getting they're they're is comfortable with to broadly pleased we so base new overall, gain with the grow we're that, earlier. more with And earlier to seeing we'll it moving those treatment up experience in the use regimen. to customer start again, in base see doing more and that So prescriber continues and our it comfort as prescribers, getting and Epidiolex more and product and

achieve epilepsy. want become that really standard very blockbuster can status remain to of care Dan confident we you treatment-resistant and we a overall, So about... in talk

Daniel Swisher

in X that in Epidiolex those of with front quarter. And those reimbursed markets, we've Yes. Spain, greater in -- as the Kim. Italy, achieved of launches in markets. Thanks, outside France U.S., X now a with sort And just had we but the Ireland importantly, in Switzerland, cycle, proposition continued earlier this launch XXXX. reminder in the on than the And just And of the going a anticipated XX% we're penetration reminder, second U.S. major Yes. value additional WAC the half, of in countries as is

we So growth as into 'XX. in that's also adding go tailwind

Bruce Cozadd

looking like based add in of anything what at are to terms hearing? on treaters you'd Rob, you're drug this how

Robert Iannone

Bruce You referred AEs, certainly... and to

Bruce Cozadd

Yes. Correct.

Robert Iannone

staying but And spend highly mean sticky we this is of who do say, I very docs lot tolerated Yes, effective, patients impression was time been that have with as my it. with familiar well very not with they see a you it. using drug are only and are as yours it

what from a perspective. So we that's affairs certainly medical continue to hear

Operator

Gary Our comes Markets. with next Nachman question Capital from BMO

Gary Nachman

fourth trigger for conversion narcolepsy? are the AG So XX% accelerating of conversion then see do aggressive be specifically sometime this second oxybate franchise Xywav to to you've that diagnosis and this considering And year? how you at half been IH, taking all, improve And of that you much as was the are if you about over awareness? the manage for that initiatives quarter, when trying at in what you doing in will the And much increase how with as year? the conversion

Bruce Cozadd

for part when and efforts in around in the appropriate significantly to IH of might about ask take us invest talk it diagnosis I'll Maybe Yes. that, be Kim to Gary, first and then increasing that.

sodium of in in never to seeing oxybate on about were your that, multiple you I'll well. Xyrem narcolepsy the patients we're not newer may come we're from conversion, referred drug sources. orphan even On patients, a remind that XX% oxybate-experienced over had just patients narcolepsy also FDA safety this they brand-new of We're they comes the from may sodium And the historically, have on But in with exclusivity It that high top certainly load. because to our who or been patients, moving with seeing first IH agent now a diagnosis decision. patients that seeing and largely part concerned been question, benefit have on though does Xywav highlighted as reduction growth oxybate. you who existing

part To So around call I'd really your of because multicomponent. it's question it just hesitate the conversion to that. second

We We Xywav as be like in what better, are would believe we that many as a from is managing product to all. possible. patients benefiting not at safer

how many market very in pleased as you soon get We've come. about want the as time. we far and has way narcolepsy a progressed to we the So takes our how that that. back no about how talk over that But know patients we're with possible to now on want been year we've Kim, efforts are see IH? just rollout in as holding in thinking on in to benefit

Kim Sablich

Yes, sure.

already a earlier, population patients So diagnosis, diagnosed of talked to substantial as no, your question because right about on is answer about whether we're now, focusing there's increased there. out we the

a that hypersomnia we can the have idiopathic formal been claims health they've of system. through actively in patients only and XX,XXX last diagnosis data with Specifically, year, see engaging not the that that, that care

market and and patients the antidepressants or that's are the and health have for there's these just still is for greater there. So back currently Many tried off-label. these or wake-promoting the care products, agents a not taken their hear of And stimulants providers, patients unmet needs we tremendous traditional relief need from meeting patients.

So the market is there.

more that idiopathic and HCPs that Xywav the anything, about And try in and identify profile. So more help to confident patients to we're their a out diagnosed from trying benefit there those are diagnosis educating with product hypersomnia. for just really become would if

Operator

from question next David Our with comes Sandler. Amsellem Piper

David Amsellem

if be Epidiolex, couple. the happening. that, clearly it's much extent are Is stimulants there a just and/or in this. overall talk been KOL United the to of I I to If Are States? you to in then But diagnosed, patients? or missed of on patients of IH. usage off-label a number are That's getting modafinil How on mix? have mainly kind can of the treatment-naive these newly And patients days. know would in that talk growth apologize therapy? two it's that trajectory could number a about I can you you talk exposed our they who So is helpful. On conversations, early is the factor product the one.

Bruce Cozadd

Maybe Rob Yes. both these. David, I'll take have of

we On the used talking got and being on already our can certainly Epidiolex is I'm the often about we agents patients that sure what based of they've side, launch, tried the we've in then again, back trials stimulants. granular modafinil refer tried in not just hypersomnia how side, other idiopathic or the data, have saw and on early to terms think but what super And drug we clinical how understanding. in other

So Rob?

Robert Iannone

Yes.

think, activity practitioners, about indications treat Epidiolex those the seizure across Epidiolex neurologists different with is syndromes, starting but across the So syndromes. is, seizure what within types I types and as notable

broadly major And that so it's active viewed different as being across of occur. number a types of seizures

of daytime sufficient so alerting Xywav. information benefit derive the that, while And they is agents prescribers. we And wouldn't the clinical despite promote agents. or trial, certainly, to With had on wake-promoting that came majority daytime from in on available in IH And off-label, regard not enrollment. were trial scores for severity whether for patients

Bruce Cozadd

with And I'll today the agents, them some say even success many wake-promoting in have stopped have limited of agents. for them stimulants sometimes of are trying so the those past not and on daytime or patients tried who

Operator

Our comes with Ty next question Navann Citi. from

Navann Ty

target? And Just this in Epidiolex key expect can in second second on markets? you launch do comments, your on substantial bolt-ons BD expect X.X outside a more other a in once billing and half? European potentially then the the you one clarification we from leverage the U.S. launch And the year reached France of to Do you expect

Bruce Cozadd

Epidiolex ex-U.S. Yes. Dan, you in could jump Renée, then, start you question. could the And second maybe if on with

Daniel Swisher

Yes.

much depends through. authorities, of there cadence on price important and to just have launch we're we're the France. goes in for a in the French dialogue And only -- you chance have active France, it that sort of with in but more land us the to saying right it's launch how On because one XXXX, on in really the price

launch but price -- So get XXXX. will a a we're we get in and that confident to to

provide future. major European active XX provide plenty could France XX and Pac the that Asia of in the towards up to smaller be And of where approval, we've like have there's that there's only countries but the countries, meaningful and growth thoughts can growth. countries launches development Importantly, last we date. would Japan meaningful plans add got

Renée Galá

to in This just Yes. development. I'll the Renée. corporate your on here is chime question part adding of and second

expect and expertise in of to XXXX. as to pipeline then continue course, a in sleep. activities all tumors to position business us. side R&D studies across Also So tremor piece. there the remarks, our at within corporate oncology actively now is in mentioned oncology, development opportunities are This commercial expand be to all our opportunities to the and on future looking of additional had solid asset across We're align and areas looking interest. side, active market-leading do areas PTSD and our And with we the I essential prepared the with in neuroscience that also would their epilepsy of on interest augment

SpringWorks along on something for expect the smaller size side product. would PharmaMar, of like slightly was dollars into think convert what larger for active anything us upfront XXXX, an a and clearly executed hundred or being I a cash which of to on great be throughout could a smaller we of probably us or you to asset million about even way with the important revenue-generating Zepzelca couple and side type transaction a Redx lines this So

supporting year in expanding are focused on addition from to deleveraging the this pipeline. ongoing We a capital allocation launches, standpoint our

And expect we to well then do target optionality to we great beyond. leverage be think beyond also we have [indiscernible]. expect in and XXXX enter positioned stated So we X.Xx, we're as active getting meet I below but and that, would net of our

Our ability cash our lever execute to effectively. demonstrated operations GW amount transaction, as ability their a able significant delever up following generates and both to business that we've the demonstrated as we but the flow, of be to to also transaction and integrate rapidly well quickly

Operator

Greg our then question from Truist comes Fraser with last Securities. And

Gregory Fraser

to have of if between patient for expect Xywav twice what over On been the average data and has that? early normalize the dosing would at And dose the you you terms on nightly per it once where mix in trends IH, time?

Bruce Cozadd

or seen end with. Yes. we clinical in tell on different up twice-nightly we from and saw in what anything anything I people that dosing would would of answer our once-nightly in since launch what say, us Greg, terms haven't trials to that, dose

which could we did is hypersomnia So to to I'll that. dosing we jump remind see steal idiopathic we lower narcolepsy. and see ask saw the the in Rob say same people slightly nightly maybe on the essentially than just in what very in on half, second I thunder

Robert Iannone

right, Yes. That's Bruce.

the large, than clinical some trial dosing nightly. So position that With up benefit from they be the take majority were benefit patients titrated clinical total on narcolepsy, that dose. to in the of by little as the narcolepsy. on ended from derive which up. And better a patients great once to it's overall and might And similar second twice and nightly, started of then very drug, trial we're on different idiopathic the a hypersomnia,

to twice And so transition tended even started there over nightly. nightly those -- to on once who were

Operator

remarks. turn At Cozadd over call like to for to I'd closing any Bruce the back time, this

Bruce Cozadd

thanks, happier Vision All operator, I with about year for strong XX%, this and everyone, be guidance growth, to midpoint ANI for on XX% ANI, our revenue track right. year-over-year us. couldn't and up achieve puts fourth year think quarter that Thanks, up and XX%, right revenue joining with XXXX. I us XX% contemplates really

Jazz for by toward all and well. Thank close on We their continued call therapeutic successfully dedication our all and and confidence I year joining XXXX. and and progress creativity their partners new forward delivering colleagues today's our updating to we of XXXX you And these So thank our want us drive for you for our and tenacity, shareholders this to to also let guidance Vision recognizing patients. me stay look as support. options

Operator

program. the concludes This

You disconnect. may now

Jazz Pharmaceuticals (JAZZ) 2 Mar 222021 Q4 Earnings call transcript